Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  binimetinib
Find trials that include:  Any drugs shown
Results 1-16 of 16 for your search:
Start Over
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ARRAY-162-311, NCI-2013-00934, 2013-000277-72, NCT01849874
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CMEK162B2301, NCI-2013-01414, NCT01909453
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2109, NCI-2012-00874, 2011-002578-21, NCT01449058
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CMEK162X2110, NCI-2012-00964, 2011-005875-17, NCT01543698
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CMEK162X2114, NCI-2013-01329, NCT01781572
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2116, NCI-2014-00903, 2013-001986-18, NCT01927341
Binimetinib and Imatinib Mesylate in Treating Patients with Untreated Advanced Gastrointestinal Stromal Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-162, NCI-2013-02281, NCT01991379
Binimetinib in Treating Patients with Relapsed, Refractory, or Poor Prognosis Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0116, NCI-2014-01518, NCT02089230
Nilotinib and Binimetinib in Treating Patients with Refractory or Advanced Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0128, NCI-2015-00044, NCT02225574
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLGX818X2109, NCI-2015-00412, NCT02159066
Intermittent LGX818 and MEK162 in Treating Patients with Metastatic Melanoma Who Have BRAFV600 Mutations
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-000616, NCI-2014-01971, NCT02263898
MEK inhibitor MEK162 and Erlotinib Hydrochloride in Treating Patients with Stage IV Non-small Cell Lung Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17361, NCI-2013-02386, CABC123D4567, CMEK162XUS04T, MCC 17361, NCT01859026
MEK Inhibitor MEK162 in Combination with Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients with Advanced Metastatic Colorectal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13355, NCI-2014-00051, CMEK162AUS09T, NCT02041481
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: HEMAML0030, NCI-2014-00169, NCT02049801
Binimetinib in Combination with Docetaxel in Treating Patients with Previously Treated, Stage IV Non-small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-001595, NCI-2015-00618, Garon MEK162 NSCLC, NCI-2015-00440, NCT02451865
Start Over